SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

Abecma

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and on the market (US approval March 2021; EU approval also granted).
Why 4/10
Abecma is already approved and commercialized with no pending regulatory decision or pivotal readout in the next ~12 months. For a large diversified pharma like BMY (~$50B revenue), Abecma is a small part of the portfolio. Per the rubric, an approved drug with no upcoming binary catalyst scores 3-5, and Abecma's modest revenue contribution places it at a 4.
Actionable Insight NEUTRAL

The next relevant event for the BCMA CAR-T competitive landscape is the FDA PDUFA date of December 23, 2026 for Gilead/Arcellx's anito-cel, which would introduce a third BCMA-directed CAR-T into the US multiple myeloma market. For BMY investors, Abecma's trajectory is more likely to be influenced by broader company dynamics (patent cliff on Eliquis/Opdivo, pipeline readouts for other assets) than by this single drug, which is an approved, mature product facing competitive erosion.

Price Chart

Loading chart...

Executive Summary

Abecma (idecabtagene vicleucel) is a BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma, approved by the FDA in 2021 and expanded to earlier treatment lines in 2024 based on the Phase 3 KarMMa-3 trial. It is fully owned and commercialized by Bristol Myers Squibb (BMY) after its 2025 acquisition of former partner 2seventy bio. While the label expansion and REMS removal are positive, the drug faces fierce competition from J&J/Legend's Carvykti, which is taking significant market share. Abecma generated ~$242M in US sales in 2024, a modest figure within BMY's overall ~$50B revenue base. No near-term binary catalyst is expected for this mature, approved asset.

How It Works

A personalized cell therapy (CAR-T) where a patient's own T cells are genetically reprogrammed to recognize and kill cancer cells that carry a protein called BCMA, which is found on multiple myeloma cells. The modified cells are infused back into the patient as a one-time treatment.

Trial Status

Abecma was initially FDA-approved in March 2021 for relapsed/refractory multiple myeloma after 4+ prior lines of therapy. The label was expanded in April 2024 to include patients after 2+ prior lines, based on the Phase 3 KarMMa-3 trial which showed a median progression-free survival of 13.3 months vs 4.4 months for standard regimens, a 51% reduction in the risk of disease progression or death. Updated KarMMa-3 results with ~31 months of follow-up were presented at the 2026 Tandem Meetings. The FDA removed the REMS program requirement for Abecma in June 2025 as part of label streamlining.

The Two-Sided Case

▲ Bull Case4
Abecma is the only CAR-T with Phase 3 randomized data (KarMMa-3) showing superiority over standard regimens in triple-class-exposed relapsed/refractory multiple myeloma, with a 51% reduction in the risk of disease progression or death.
FDA label simplification in June 2025 (removal of REMS program and reduced monitoring requirements) removes a barrier to adoption and should support continued commercial uptake.
Bristol Myers fully acquired 2seventy bio in 2025, consolidating 100% of Abecma economics and manufacturing control, eliminating the prior profit-share arrangement.
The CAR-T therapy market is forecast to grow from $7.24B in 2026 to $13.78B by 2031, and Abecma is one of only two BCMA-directed CAR-Ts currently approved in the US alongside Carvykti.
▼ Bear Case4
Abecma faces severe competitive pressure from Carvykti (J&J/Legend), which has demonstrated superior efficacy in head-to-head comparisons and is rapidly gaining market share, with Abecma sales declining ~21% in Q1 2026 vs Carvykti growing 96%.
A third BCMA CAR-T competitor, anito-cel (Gilead/Arcellx), has a PDUFA date of December 23, 2026, which would further fragment the addressable multiple myeloma population.
Within Bristol Myers' ~$50B annual revenue, Abecma's estimated ~$250M in US sales (2024 full year) is a very small contributor, making it unlikely to move the stock meaningfully as a stand-alone catalyst.
BMY analyst consensus is mixed (8 Buy, 18 Hold, 1 Sell, 7 Strong Buy), the stock trades at a P/E of ~9x, and recent analyst actions show one downgrade (Leerink: Outperform to Market Perform) and one upgrade (Argus: Hold to Buy) in the last 90 days, reflecting uncertainty about the company's growth trajectory.

Upcoming Catalysts

  • No pending FDA decision or pivotal readout scheduled for Abecma specifically in the next ~12 months. The competitive landscape shifts on December 23, 2026, when the FDA decides on Gilead/Arcellx's anito-cel, a new BCMA CAR-T competitor.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 13

Hover a chip for the title
1 fda.gov2 news.bms.com3 news.bms.com4 myeloma.org5 pharmaceutical-technology.com6 biospace.com7 biospace.com8 fda.gov9 cancernetwork.com10 eureka.patsnap.com11 vcbeathealth.com12 reuters.com13 stockstory.org